comparemela.com

Latest Breaking News On - Shauna dillon - Page 7 : comparemela.com

ObsEva SA: ObsEva Announces Corporate Updates

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland - July 27, 2022 - ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel

Shauna dillonKatja buhrerExchange commissionCompany executive committeeSwiss exchangeFabien de ladonchampsChief administrative officerExecutive committeeNasdaq global select marketPrivate securities litigation reform actNew drug applicationRisk factorsAnnual reportEva excom

ObsEva Announces Corporate Updates

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United kingdomYuyuan bioscienceShauna dillonKatja buhrerJeanene timberlakeExchange commissionEuropean commissionDrug administrationSwiss exchangeNew drug applicationPrescription drug user fee actUnited kingdom medicinesHealthcare products regulatory agencyLicense agreementSublicense agreementNasdaq global select market

ObsEva Announces Corporate Updates - Benzinga - Press Release

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss ExchangeGENEVA, Switzerland – July 27, 2022 – ObsEva SA OBSVOBSN)), a biopharmaceutical co

Shauna dillonExchange commissionCompany executive committeeSwiss exchangeFabien de ladonchampsChief administrative officerExecutive committeeNasdaq global select marketPrivate securities litigation reform actNew drug applicationRisk factorsAnnual report

Investegate |ObsEva SA Announcements | ObsEva SA: ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

Investegate announcements from ObsEva SA, ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

United statesUnited kingdomGreat britainShauna dillonKatja buhrerBrian ocallaghanExchange commissionEuropean commissionHealthcare products regulatory agencySwiss exchangeObseva announces united kingdomUnited kingdom medicinesBriano callaghanAbout yseltyNasdaq global select marketCentral research laboratories

ObsEva SA: ObsEva Announces UK MHRA Marketing Authorization for Yselty (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

-Yselty (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty; ObsEva to

United statesUnited kingdomGreat britainShauna dillonKatja buhrerBrian ocallaghanExchange commissionEuropean commissionHealthcare products regulatory agencySwiss exchangeUnited kingdom medicinesBriano callaghanAbout yseltyCentral research laboratoriesPrivate securities litigation reform actNew drug application

vimarsana © 2020. All Rights Reserved.